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Although vascular dysfunction is a major suspect in the etiology of
several important neurodegenerative diseases, the signals in-
volved in vessel homeostasis in the brain are still poorly under-
stood. We have determined whether insulin-like growth factor I
(IGF-I), a wide-spectrum growth factor with angiogenic actions,
participates in vascular remodeling in the adult brain. IGF-I induces
the growth of cultured brain endothelial cells through hypoxia-
inducible factor 1 and vascular endothelial growth factor, a
canonical angiogenic pathway. Furthermore, the systemic injection
of IGF-I in adult mice increases brain vessel density. Physical
exercise that stimulates widespread brain vessel growth in normal
mice fails to do so in mice with low serum IGF-I. Brain injury that
stimulates angiogenesis at the injury site also requires IGF-I to
promote perilesion vessel growth, because blockade of IGF-I input
by an anti-IGF-I abrogates vascular growth at the injury site. Thus,
IGF-I participates in vessel remodeling in the adult brain. Low
serumbrain IGF-I levels that are associated with old age and with
several neurodegenerative diseases may be related to an increased
risk of vascular dysfunction.
A fter vessel formation has been completed during development,brain angiogenesis is maintained mostly to match functional
demands. Vascular remodeling may also take place in the adult
brain in response to specific stimuli such as injury or physical
exercise (1, 2). In the case of brain injury, vessel sprouting usually
leads to distorted neovascularization, probably because of a dis-
turbed tissue architecture and scar formation; in response to
physical exercise, new vessels develop within an unperturbed
environment and appear normal. Because similar angiogenic
mediators are present during development and in the adult, it is
considered that, at the molecular level, angiogenesis in the adult
brain is similar to that seen during development. However, this
remains to be shown.
A potential candidate signal in this regard is insulin-like growth
factor I (IGF-I) a well known angiogenic factor (3). Studies suggest
that IGF-I modulates vessel formation during brain development
(4), and that IGF-I may be involved in diabetic retinal neovascu-
larization (5) and possibly in age-related changes in brain vascula-
ture (6). It has recently been shown that both brain-derived and
circulating IGF-I act as a neuroprotective signal in the adult brain
(7). For instance, both local (8) and serum (9) IGF-I protect against
brain injury. Serum IGF-I also is important for mediating the
protective effects of physical exercise on the brain (10). Because
reactive vessel remodeling occurs after both injury and exercise, an
additional neuroprotective action of IGF-I might be to favor brain
angiogenesis in response to injury andor exercise. In this study, we
have explored these possibilities.
Materials and Methods
Animals. Wistar rats and C57BL6 mice from our inbred colony
were used in the study. Mutant mice with low serum IGF-I were
generated by disrupting the liver IGF-I gene (liver IGF-I-deleted,
or LID) mice with the albumin-CreLox system, as described (11).
Lack of liver IGF-I results in a 60% decrease of serum IGF-I levels,
whereas in the rest of the body, including the brain, serum IGF-I
levels are normal (11). Mice that are deficient in serum IGF-I do
not exhibit developmental defects, probably because the levels of
IGF-I in serum start to decline when development is already
completed (11, 12). Lox/Cre littermates were used as controls.
Male mice 2–3 months old were used throughout the study.
Wild-type mice were included as additional controls because
they are congenic to the original FVBN LID breeders. The
animals were kept under standard laboratory conditions in accor-
dance with European Communities Council guidelines (directive
86609EEC).
In Vitro Assays. The brain endothelial cells were cultured as de-
scribed (13), with minor modifications. The purified endothelial
cells (over 95% CD31) from P7-8 rat pups were cultured in
DMEM-F12  10% FCS  EGF (10 ngml, Sigma). Before
treatments, the cells were placed in serum-free medium (14). Cell
proliferation was determined by using a commercial 3-4,5-
dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide assay
(Roche Diagnostics), nine wells per group. Tubulization of the
endothelial cells was monitored with a 3D collagen culture system
(Chemicon), and the cells were processed for lectin immunocyto-
chemistry. In transfection assays using FuGENE reagent (Roche
Diagnostics), the cells (5 105 cells per well in 12-well plates) were
transfected by using a dominant negative mutant hypoxia-inducible
factor 1 (DN-HIF-1) with a hemagglutinin epitope tag cloned in
the pcDNA3 vector (15) and maintained in DMEM-F12  10%
FCS. An empty vector was used as a control for mock transfections.
IGF-I (GroPep, Adelaide, Australia) and vascular endothelial
growth factor (VEGF) (Sigma) were used at 107 M.
In Vivo Procedures. To determine the effects of exercise on endo-
thelial cell proliferation, LID mice and control littermates running
daily in a treadmill (10) received i.p. injections of BrdUrd (50
mgkg, 3 days per week). Mice ran for 1 h at 12 mmin for 4 weeks,
whereas control animals remained in the treadmill without running.
In a second type of experiment, we administered IGF-1 s.c. either
by using an Alzet 2001 osmotic minipump (Alzet, Palo Alto, CA)
(50 gkg per day for 2 weeks) or through injection of IGF-I
microspheres (100 gkg per day, once every week for 1 month) as
described (16). Control animals received saline.
To assess the effects of brain injury on neovascularization,
cortical stab wounds were performed in deeply anesthetized LID
and control mice. A 26-gauge needle was inserted 3 mm from the
surface of the brain (1.3 to 2–7 mm caudal to bregma, 1.5 mm
lateral) (17). Animals were allowed to survive for 1, 3, 14, or 28 days.
In a separate set of experiments, brain-injured LID mice received
a s.c. infusion of a blocking anti-IGF-I over 28 days, as described
elsewhere (9). Control groups of injured LID mice were infused
with either nonimmune rabbit serum (NRS) or vehicle (saline). To
determine perilesional changes in angiogenic markers and vessel
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density, a block of brain parechyma surrounding the stab wound (2
mm wide, 4 mm high) was dissected from each animal.
Immunoassays. The animals were perfused transcardially with sa-
line. The right brain hemisphere and hemicerebellum were re-
moved and fixed for 24 h at 4°C by using 4% paraformaldehyde in
0.1 M phosphate buffer (PB, pH 7.4). Fifty-micrometer coronal
sections were cut rostrocaudally by using a vibratome (Leica,
Cambridge, U.K.) and immersed in 0.1 M PB. The left hipoccampi
and the other half of the cerebellum were kept at 80°C for
immunoassays. Two series of sections per animal were used for
performing cell counts. The other series were used for immuno-
cytochemistry. Antibody incubations were performed by using 0.1
M PB0.5% Triton X-1000.3% BSA. For BrdUrd detection, DNA
was denatured by using 2 M HCl for 30 min at room temperature.
A rat anti-BrdUrd antibody (1:5,000; Developmental Studies Hy-
bridoma Bank, Iowa City) and biotinylated tomato lectin (1:300;
Vector Laboratories) were used for staining of DNA-synthesizing
cells and endothelial cells, respectively. A monoclonal anti-HA tag
(1:1,000; Cell Signaling Technology, Beverly, MA) was used to
detect transfected cells. The secondary antibody was a biotinylated
rabbit anti-rat IgG (1:1,000; Sigma) followed by the VECTASTAIN
ABC kit (Vector Laboratories). For double BrdUrd-lectin staining,
we used goat anti-rat IgG-Alexa Fluor 488 (1:1,000; Molecular
Probes), anti-rabbit IgG-Alexa 594, anti-mouse IgG-Alexa Fluor
594 (1:1,000; Molecular Probes), or rhodamine-labeled tomato
lectin (1:200; Vector Laboratories).
A Western blot analysis was performed by using the tissue and
cell culture extracts, as described (18). Anti-VEGF (Oncogene
Science); anti-VEGF receptor 1 (VEGFR1) and 2 (VEGFR2),
anti-angiopoietin-12 (all from Santa Cruz Biotechnology); anti-
HIF-1 (Stressgen Biotechnologies, Victoria, Canada); and anti-
CD31 (Pharmingen) were used. An anti-PI3K was used to re-blot
the membranes to ensure equal protein load. The protein levels
were expressed relative to protein load in each lane. Densitometric
analysis was performed by using SCION IMAGE software (Scion,
Frederick, MD). A commercial VEGF ELISA (R & D Systems)
was used to quantify brain homogenates according to the manu-
facturer’s instructions.
Morphometry. Morphometrical analyses were performed as de-
scribed (19). In brief, BrdUrd cells were quantified by using an
unbiased stereological method with the optical dissector (20).
Parallel 50-m sections were obtained. Only nuclei that were
completely filled or that showed patches of immunostaining of
variable intensity were considered as BrdUrd. To determine the
Fig. 1. IGF-I promotes brain angiogenesis. (A) IGF-I (107 M)
stimulates proliferation of cultured brain endothelial cells as
determined with the 3-4,5-dimethylthiazol-2-yl-2,5-diphenyl
tetrazolium bromide assay. VEGF (107 M) was used as a positive
control [n  3 independent experiments (nine replicates per
experiment)]. (B) In the presence of IGF-I (107 M) endothelial
cells plated on collagen form tubular structures, a prerequisite
in the angiogenic process. Endothelial cells were labeled with
tomato lectin (red). Note the absence of tubes under control
conditions. (C) IGF-I stimulates both VEGF (upper gel) and
VEGFR1 (lower gel) in endothelial cell cultures. Representative
Western blots are shown. Lower gels show blots that were
re-assayed with anti-PI3K antibody to control for protein load.
Histograms show densitometric quantitation of the blots. **,
P 0.01; ***, P 0.001 vs. control, n 5. (D) The transcriptional
modulator HIF-1 is required for IGF-I-induced activation of
VEGF synthesis. (Top) Representative microphotograph of an
endothelial cell monolayer transfected with HA-tagged DN-
HIF-1. Cells were stained with anti-lectin (green) and anti-HA
tag (red). Note the nuclear location of mutant HIF-1. (Middle)
Representative VEGF blot of cultures transfected with empty
pcDNA3 vector (control) and DN-HIF-1. IGF-I increases VEGF
only in mock-transfected cultures. Re-blotting with anti-PI3K
shows an equal protein load in all lanes. (Bottom) Densitometric
quantitation of five independent experiments. ***, P  0.001
vs. all other groups. (E) A 2-week s.c. infusion of IGF-I (50 gkg
per day) elicits a significant increase in vascularization of the
adult mouse brain. (Top) Vessels were identified with biotyni-
lated-tomato lectin (arrow) and the percent surface of brain
parenchyma covered with vessels estimated by scoring vessel
contacts with the points of the grid (a 36-point grid is shown).
(Scale bar  25 m.) (Middle) The histograms indicate vessel
density in the cerebellum and the hippocampus as percent of
control (100%). *, P  0.05 vs. saline-treated controls (n  5
animals per group). (Bottom) Representative cerebellar section
with lectin-positive vessels of saline and IGF-I-treated mice.
Vessel density is increased after IGF-I treatment. ML, molecular
layer; GL, granule cell layer. (Scale bar  50 m.)
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cell density, the counting area was drawn by using a camera lucida.
The area was then estimated by using the point-counting method of
Wiebel (21). Double immunohistochemistry was performed in the
adjacent sections of each animal. We counted three to four areas
per section and five to six sections in each animal.
Similarly, for our analysis of brain vasculature, photographs were
taken and a semiquantitative analysis of vessel density was per-
formed according to the point-counting method (21) on sections
that were immunostained with lectin. The number of point inter-
sections of lectin-positive profiles were scored in a 100-point grid
used for the hippocampus and the cortex and in a 36-point grid used
for the cerebellum. The grid covered the entire surface of the
microscopic field so that surface area was calculated according to
the magnification used (100 for the hippocampus and cortex and
40 for the cerebellum). In an example shown in Fig. 1E, the grid
covers only part of the microscopic field for the sake of clarity.
Vessel density is expressed as the percent of brain surface covered
with vessels. The measurements were performed in 20 fields per
section, with eight sections per animal (five to six when using
cortical sections).
Statistical differences between groups were determined by using
the two-tailed Student t test.
Results
IGF-I Promotes Angiogenesis in the Brain. We first determined
whether IGF-I increases brain vessel growth. As reported for
endothelial cells in other areas (22, 23), brain endothelial cells
increase their proliferation and tubulize in response to IGF-I (Fig.
Table 1. Levels of angiogenic-related proteins in different brain regions of
serum-IGF-I-deficient (LID) mice
VEGFR1 VEGFR2 CD31 Tie-2 Ang-1 Ang-2 VEGF HIF-1
Cortex 54  22 86  16 170  51 81  23 71  8 107  17 146  17 89  15
Cerebellum 132  38 120  23 107  23 90  41 101  21 94  12 77  6 101  15
Hippocampus 133  38 94  19 108  23 143  50 62  15 103  17 65  17 95  19
Values are expressed as percent  SEM of levels found in control littermates. No significant differences were
found for any of the proteins evaluated.
Fig. 2. Serum IGF-I is needed for exercise-
induced vessel growth in the brain. (A)
Exercise induces proliferation of endothe-
lial cells only when serum IGF-I levels are
normal. (Upper) Fluorescently labeled mi-
crophotograph of a newly formed brain
vessel with BrdUrdnuclei co-labeled with
tomato lectin in the cytoplasm. (Lower)
Exercise (E) significantly increased the
number of double-labeled BrdUrdlec-
tin cells, compared with sedentary (S)
mice in the cerebellum of control litter-
mates but not in LID mice with low serum
IGF-I (*, P  0.05 vs. sedentary; n  4 ani-
mals per group). (B) Vessel density in the
cerebellum increases after exercise only in
control mice or in LID mice treated with
IGF-I, but not in LID mice treated with
saline while running (**, P  0.01 vs. sed-
entary mice; ***, P  0.001 vs. exercised
LID mice). (C) Similarly, levels of CD31, an
endothelial marker, increased only in ex-
ercised control mice. The upper gel shows
a representative blot of CD31. The lower
gel shows protein load per lane assessed
by re-blotting with anti-PI3K. The histo-
gram shows quantitation of CD31 blots
after correcting for protein load (***, P
0.001 vs. sedentary controls; n  4 per
group). (D) Brain levels of VEGF were not
modified by exercise. The upper gel shows
representative VEGF blots after 1 month of
exercise. The lower gel shows the control
for protein load. Quantitation is shown in
the histogram (n 4). (E) On the contrary,
brain levels of HIF-1were increased after
exercise only when serum IGF-I levels are
normal. The upper gel shows a represen-
tative HIF-1 blot after 1 month of exer-
cise. The lower gel shows the PI3K control
re-blot. Histograms illustrate significant
increases in exercised control mice (***,
P  0.001; n  4).








1 A and B). In addition, VEGF and VEGFR1 are up-regulated by
IGF-I (Fig. 1C). Stimulation of VEGF by IGF-I requires the
transcriptional modulator HIF-1, which is involved in angiogenesis
(24). The transfection of cultured endothelial cells with a DN-
HIF-1 mutant inhibits the increase in VEGF induced by IGF-I
(Fig. 1D). The levels of other proteins related to angiogenesis such
as VEGFR2, angiopoietin-1-2, or Tie-2 were not modified by
IGF-I (data not shown).
Because IGF-I receptors are localized in the luminal side of brain
vessels (25), circulating IGF-I can directly signal onto the brain
endothelial cells and modulate their growth in vivo also. Indeed, the
systemic administration of IGF-I promotes brain vessel formation
(Fig. 1E) and increases brain VEGF levels: from 170 ngg protein
in controls to 360 ngg after IGF-I in the cerebellum, and from 133
ngg to 310 ngg in the hippocampus (P  0.05, n  5). After a
2-week s.c. infusion of IGF-I in adult mice, the density of the
vasculature was markedly augmented (P  0.05, Fig. 1E) in two
different brain areas, the cerebellar molecular layer (vessel density
in controls is 18.2  2%) and the hippocampal granular and
subgranular layers (controls: 27 1%). Therefore, IGF-I is a brain
angiogenesis promoter.
IGF-I in Exercise-Induced Brain Vessel Growth. The beneficial effects
of exercise on the brain are blocked when the serum IGF-I input to
the brain is reduced (9, 10, 19). To determine whether the angio-
genic response to exercise is also modulated by circulating IGF-I, we
examined exercise-induced angiogenesis in mice that had normal
levels of IGF-I in the brain (95% of the levels of control littermates,
n  6), but greatly reduced levels in serum [LID mice, (11)].
Importantly, although LID mice have increased brain  amyloid
and moderate gliosis (26), these alterations do not affect the brain
levels of proangiogenic mediators such as VEGF and their recep-
tors, of endothelial markers such as CD31, and of other proteins
related to vascular remodeling including the angiopoietins and their
receptors, or HIF-1 (Table 1).
Normal mice showed enhanced proliferation of brain endothelial
cells after physical exercise (Fig. 2A). For instance, in the cerebellar
cortex, the total number of BrdUrd cells increased from 199 19
to 285  17 cells per mm3 in response to 1 month of exercise. Of
these, 38% were associated with the endothelial marker lectin.
Other BrdUrd cells were associated with the pluripotent marker
nestin but not with glial (glial fibrillary acidic protein and OX42) or
neuronal antigens (3 tubulin and -aminobutyric acid type A
Fig. 3. Vessel remodeling after brain trauma. (A) Density of vessels in the area surrounding the lesion significantly increases in control as well as in LID mice
(***, P 0.001; n 4 animals per group). (B Left) Fluorescence photomicrographs of the perilesion site (arrow) in LID mice showing IGF-I immunoreactive cells.
The majority of the IGF-I cells are astrocytes (GFAP) as determined by confocal analysis (Merge). Control littermate mice show an identical local IGF-I response.
(Bars 50m.) (Right) Neovascularization is restricted to the perilesioned area as determined by lectin staining of brain vessels. The arrow indicates the cannula
tract (14 days after injury). Note the heavy lectin staining concentrated around the lesion area. (Scale bar  100 m.) (C) Levels of HIF-1 increase 3 days after
injury in the perilesion area in both groups, although in LID mice, the increase is smaller. The upper gel shows a representative HIF-1 blot, and the lower gel
shows the control of protein load with anti-PI3K. Histograms show densitometric quantitation of HIF-1 (***, P 0.001 vs. sham-injured mice; n 4). (D) Levels
of VEGF around the lesion area increase 3 days after injury in both experimental groups. The upper gel shows a representative VEGF blot, and the lower gel shows
the control of protein load. Histograms show quantitation of VEGF (**, P  0.01 vs. sham mice; n  4).
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receptor 6 subunit; data not shown). In LID mice, this response
was absent. No increases in the number of endothelial cells, vessel
density, or in the levels of the endothelial cell marker CD31 were
seen (Fig. 2 A–C). This lack of vessel growth after exercise in LID
mice was corrected by simultaneous infusion of IGF-I during
training (Fig. 2B). Accordingly, a threefold increase in CD31 levels
in IGF-I-treated vs. saline-treated exercising LID mice was found
(from 177.5  11 densitometric units in saline-treated to 542.5 
8.5 in IGF-I-treated mice; n 4; P 0.001). Endothelial cell growth
was determined also in the hippocampus, where similar responses
to exercise were found. As previously documented, a higher total
number of BrdUrd cells and a greater increase in the number of
BrdUrd cells stained with neuronal markers such as NeuN or 3
tubulin was seen in this brain area (data not shown).
Levels of the angiogenic markers VEGF and HIF-1 were also
analyzed. VEGF was not affected by exercise either after 3 (data
not shown) or 30 days (Fig. 2D), as determined by using Western
blot analysis and confirmed by using ELISA (data not shown). The
levels of HIF-1were significantly increased in control mice but not
in LID mice, at both early (3 days; data not shown) and late (30 days;
Fig. 2E) times after exercise.
IGF-I in Injury-Induced Brain Angiogenesis. Increased local synthesis
and accumulation of IGF-I is a typical response to brain injury (27).
The cells surrounding the lesion site, mostly astroglial cells, contain
higher IGF-I and IGF-binding protein immunoreactivity after
injury (28, 29). Fig. 3B (Left) shows the up-regulation of IGF-I levels
in astrocytes surrounding the lesion in LID mice. Control litter-
mates show an identical up-regulation. Therefore, brain insult with
damage to the blood–brain barrier results in accumulation at the
lesion site of IGF-I that probably originated from both local
increased synthesis and from the circulation. We examined the
contribution of serum IGF-I to this type of reactive angiogenesis by
determining the angiogenic response to a stab wound in LID mice.
After 2 weeks, increased vessel density in the perilesion area (Fig.
3B Right) is similar in both LID and control mice (Fig. 3A). This
increase in vessel density is preceded by enhanced levels not only of
HIF-1, but also of VEGF, peaking at 3 days after injury (Fig. 3 C
and D) and returning to basal values after 30 days (data not shown).
LID mice have a similar response, although with a smaller increase
in the levels of HIF-1.
To determine whether IGF-I is required after injury-induced
angiogenesis, we administered to LID mice a chronic s.c. infusion
of a blocking anti-IGF-I antibody. As shown in detail before, this
treatment effectively blocks IGF-I input to the target cells within
the brain (9). Under these conditions, early activation of HIF-1
and VEGF in the perilesion area was significantly attenuated (Fig.
4 A and B). Moreover, 1 month after injury, vessel density in the
perilesional area remained within control values in anti-IGF-I-
infused animals, whereas mice that were injected with either saline
or normal serum showed prominent vessel growth (Fig. 4 C and D).
Discussion
IGF-I is a ubiquitous growth factor present at high levels in the
circulation and synthesized in many organs, including the brain (30).
Fig. 4. Local IGF-I is required for lesion-induced angiogenesis. (A) LID mice receiving a s.c. anti-IGF-I infusion simultaneously to the lesion show a significantly
diminished increase in VEGF levels 3 days after the lesion, compared with control injured animals receiving either NRS infusion or saline. The upper gel shows
a representative VEGF blot. The lower gel shows the PI3K blot for control of protein load. Histograms indicate quantitation of VEGF levels in the perilesion area
(**, P  0.01 vs. NRS and saline-treated brain injured mice; n  4). (B) Similar results are found in peak HIF-1 levels 3 days after injury in anti-IGF-I-treated LID
mice. The upper gel shows the HIF-1 blot, and the lower gel shows the protein load control with PI3K. Histograms show that HIF-1 is significantly diminished
in the anti-IGF-I group (**, P 0.01 vs. NRS and saline treated; n 5). (C) Lectin immunocytochemistry of the perilesioned site indicates prominent vessel growth
after 1 month of stab injury in saline-treated LID mice, whereas after infusion of anti-IGF-I, angiogenesis is absent. The white arrow indicates the position of the
cannula tract. (Scale bar 100m.) (D) Vessel density in the perilesion area increases in saline-treated and NRS-treated LID mice, compared with sham-operated
animals, but not in injured anti-IGF-I-treated LID mice (***, P  0.001 vs. NRS and saline treated; n  4 per group).








Based on previous observations, we recently suggested that not only
brain but also systemic IGF-I is a trophic factor for the adult brain
(7). Our present observations reinforce this notion indicating that
both local and serum IGF-I play a role in brain angiogenesis.
Systemic injection of IGF-I promotes brain vessel growth. This
agrees with angiogenic actions of IGF-I in other organs (3) and the
presence of IGF-I receptors in brain vessels (25). This action of
IGF-I appears to be physiologically relevant, because in mice with
low systemic levels of IGF-I, the angiogenic response to physical
exercise, a physiological stimulus for brain vessel growth (2), was
abrogated. The impaired angiogenic response was restored to
normal when serum-IGF-I-deficient mice received IGF-I. In turn,
neovascularization after injury proceeded normally even with low
serum IGF-I. In this case, injury-induced brain accumulation of
IGF-I was required. When IGF-I input to the injured area was
blocked by anti-IGF-I infusion (9), perilesional angiogenesis was
inhibited. Local increases of IGF-I at the injury site are achieved in
part through up-regulated synthesis of IGF-I in the damaged
parenchyma (29), and through local increased levels of IGF-binding
proteins that will probably retain both brain and bloodborne IGF-I
at the lesion site (31). Therefore, due to the disruption of the
vascular bed and surrounding tissue, damaged brain vessels in the
lesioned area will have access to both brain and serum IGF-I. In the
case of serum-IGF-I-deficient mice, angiogenesis after brain
trauma was normal probably because local increased synthesis of
IGF-I together with the remaining available circulating IGF-I
appeared to be sufficient to trigger endothelial growth. Indeed, LID
mice showed increased IGF-I immunoreactivity around the le-
sioned site indistinguishable from that seen in control mice (Fig.
3B). Altogether, these data indicate that both local and blood-
derived IGF-I is essential for reactive brain vessel remodeling.
As our in vitro studies show, the molecular pathway underlying
the effects of IGF-I on brain endothelium includes HIF-1 and its
downstream effector, VEGF. Both HIF-1 (32) and VEGF (33)
were stimulated by IGF-I. However, whereas HIF-1was increased
either after injury, IGF-I administration, or physical exercise,
VEGF increased after the first two types of stimuli but not after
exercise. A possible explanation is that HIF-1 under normoxic
conditions is usually at very low levels. Therefore, any increase over
basal levels will easily be detected. On the contrary, VEGF is
constitutively expressed by endothelial cells because it is essential
for vessel maintenance. This may mean that VEGF increases
specifically in regions of vessel sprouting induced by exercise will
remain undetected because of already high overall basal levels. In
the case of increases in VEGF levels detected in vitro and in
perilesion tissue blocks, small changes in VEGF levels could be
more easily measured. At any rate, the role of VEGF in exercise-
induced angiogenesis requires further clarification.
The extent of the angiogenic response may dictate the amount of
IGF-I input that is required. When angiogenesis is a widespread
phenomenon, such as after exercise, high IGF-I input may be
required (i.e., both local and circulating IGF-I may be recruited).
When angiogenesis is a localized process, locally available IGF-I
input suffices possibly because additional injury-associated pro-
cesses such as hypoxia and pro-inflammatory cytokines also recruit
the HIF-1VEGF angiogenic pathway. Consequently, in neuro-
degenerative conditions where widespread pathology would trigger
a wide angiogenic response, it is likely that serum IGF-I input would
be required. Notably, in stroke patients and in Alzheimers disease
patients where pathology affects ample brain regions, serum IGF-I
levels are increased (34, 35), maybe to cope with the increased brain
demand of circulating IGF-I. We hypothesize that in these cases,
neovascularization of damaged brain areas will require a higher
IGF-I input.
In summary, the adult brain requires IGF-I for reactive vessel
remodeling. This proangiogenic activity of IGF-I likely contributes
to its neuroprotective actions because increased vascularization
assures proper nutrient and oxygen supply to neurons. Low IGF-I
input to the brain may compromise angiogenic responses both
under physiological and pathological circumstances, which may be
of clinical consequence.
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